Roche announced June 27 that the U.S. FDA has issued 510(k) clearance for the company's CSF Aβ42/total-tau assay to be used for the diagnosis of Alzheimer’s disease in people aged 55 and older. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback